Health & Biotech
Weed Week: Aurora Marijuanis and CBD bubble tea in Thailand
Health & Biotech
Laughing all the way to the kitchen: Nutritional Growth Solutions hits 958% growth in China
Health & Biotech
ASX Health Stocks: US market brings home the bacon for HeraMED and Respiri
Health & Biotech
Nanollose finishes milestone June quarter well positioned for growth
Health & Biotech
‘Revenues and profitability will steadily increase’: Equity firm says undervalued EZZ set up for future growth
Health & Biotech
Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success
Health & Biotech
ASX Health Stocks: INOVIQ reports good study results; Mayne Pharma launches unique oral contraceptive
Health & Biotech
Osteopore delivers three straight quarters of growth in record financial performance
Health & Biotech
Creso Pharma’s acquisition target lands deal with leading US online health marketplace
Health & Biotech
Here are the Top 10 crucial trials coming up for ASX biotechs in 2022
Health & Biotech
Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism
Health & Biotech
ASX Health Stocks: Inoviq pockets another US patent, its second in a month
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.